MedTrace Logo

MMV533 Plasmodium Falciparum Volunteer Infection Study

NCT05205941 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2024-12-02

Study results available
· View outcomes & findings →

Summary

A Phase 1b study to assess the safety, tolerability and antimalarial activity of MMV533 against Plasmodium falciparum 3D7 blood stage infection in healthy volunteers

Conditions

Interventions

DRUG

MMV688533

Not exceeding 200mg

Sponsors & Collaborators

  • Nucleus Network Ltd

    collaborator OTHER

  • Southern Star Research

    collaborator INDUSTRY

  • Medicines for Malaria Venture

    lead OTHER

Principal Investigators

  • Jason Lickliter, MD · Nucleus Network Ltd

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-03-30
Primary Completion
2022-09-02
Completion
2022-09-02

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05205941 on ClinicalTrials.gov